Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) often experience life-threatening relapses of the disease, and rituximab (RTX) can be used to mitigate relapse risk. However, the predictors of relapse in iTTP and the magnitude and duration of effect of RTX remain key unanswer...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Sun, Lova, Mack, Johnathan, Li, Ang, Ryu, Justine, Upadhyay, Vivek A., Uhl, Lynne, Kaufman, Richard M., Stowell, Christopher P., Dzik, Walter S., Makar, Robert S., Bendapudi, Pavan K.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2019
Assuntos:
Thrombosis and Hemostasis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517661/
https://ncbi.nlm.nih.gov/pubmed/31076407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031039
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares